Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Surv Ophthalmol. 2019 May-Jun;64(3):380-400. doi: 10.1016/j.survophthal.2019.02.007. Epub 2019 Feb 22.
Mycotic keratitis continues to be an important cause of corneal blindness, especially in tropical and subtropical countries. The prognosis is poor compared with many other forms of keratitis because of the lack of effective antifungal drugs. The currently available antifungal drugs suffer from multiple drawbacks such as poor ocular penetration, unpredictable bioavailability, and adverse effects associated with systemic medications. Over the last decade, several new drugs and drug-delivery systems have been introduced in an attempt to improve the treatment outcomes. Thorough knowledge of the currently available antifungal drugs, their spectrum of action, and associated adverse effects is essential to deal with cases of mycotic keratitis. We discuss the pharmacologic properties and clinical use of the currently available antifungal drugs.
真菌性角膜炎仍然是导致角膜盲的重要原因，尤其是在热带和亚热带国家。与其他类型的角膜炎相比，由于缺乏有效的抗真菌药物，其预后较差。目前可用的抗真菌药物存在多种缺陷，如眼内穿透性差、生物利用度不可预测以及与全身药物相关的不良反应。在过去的十年中，已经引入了几种新的药物和药物输送系统，试图改善治疗效果。要处理真菌性角膜炎病例，就必须深入了解目前可用的抗真菌药物、其作用谱和相关的不良反应。我们讨论了目前可用的抗真菌药物的药理学特性和临床应用。
